The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Noninferiority trials
Open accessAbstract
Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conservative analysis approach, lack of protection from bias by blinding, and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be necessary when a placebo group can not be ethically included, but it should be recognized that the results of such trials are not as credible as those from a superiority trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032
Van de Werf, F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07403-6 · Cited by 885
A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction
(1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371603 · Cited by 676
Intention to treat – who should use ITT?
Lewis, J., & Machin, D. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.402 · Cited by 235
The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371604 · Cited by 145
Ware, J. H., & Antman, E. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371610 · Cited by 125
Some Issues in the Design and Analysis of Equivalence Trials
Hauck, W. W., & Anderson, S. (1999) · Drug Information Journal · doi:10.1177/009286159903300114 · Cited by 91
Design Issues in Noninferiority/Equivalence Trials
Hwang, I. K., & Morikawa, T. (1999) · Drug Information Journal · doi:10.1177/009286159903300424 · Cited by 89
Clinical and statistical issues in therapeutic equivalence trials
Garbe, E., R�hmel, J., & Gundert‐Remy, U. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315342 · Cited by 49
Cited by
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Topol, E. J., Moliterno, D. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Cohen, D. J., Cohen, E. A., Bertrand, M., Neumann, F.-J., Stone, G. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442502 · Cited by 677
Freedland, K. E., Mohr, D. C., Davidson, K. W., & Schwartz, J. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318218e1fb · Cited by 369
Latib, A., Colombo, A., Castriota, F., Micari, A., Cremonesi, A., De Felice, F., Marchese, A., Tespili, M., Presbitero, P., Sgueglia, G. A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.020 · Cited by 364
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Evans, S. R., Rubin, D., Follmann, D., Pennello, G., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S. E., Fowler, V. G., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ495 · Cited by 361
Metadata
- Authors
- Snapinn, S. M.
- Venue
- Trials
- Published
- 2000-07-31
- Volume
- 1
- Issue
- 1
- Pages
- 19-21
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W3189355562
- Cited by
- 267
- References
- 10
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninferiority trials. https://app.cochat.ai/papers/10.1186/cvm-1-1-019
- The paper
- Snapinn, S. M. (2000). Noninferiority trials. Trials. https://doi.org/10.1186/cvm-1-1-019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.